Is the decrease of cardiovascular mortality in Poland associated with the reduction of global cardiovascular risk related to changes in life style?

BACKGROUND: After an ascending trend of cardiovascular mortality, which was observed up to the sixties, there was a declining tendency in western countries thereafter. The decrease in mortality rates in Poland has been noticed since 1991. There is an uncertainty whether this improvement in prognosis was only due to the improvement in health care level or was accomplished, to some extent, by population life style changes. AIM: To assess whether the decrease in cardiovascular mortality in Poland was accompanied by a simultaneous reduction in global cardiovascular risk profile. METHODS: The study was based on screened random samples from the Warsaw population aged 35-64 years, who were examined in the years 1984 (2646 subjects), 1988 (1433 subjects), 1993 (1539 subjects) and 2001 (853 subjects). The group evaluated in 1984 was followed up for 10 years with all fatal events recorded (364 deaths were registered including 166 cardiovascular deaths). The model of 10 years probability of total and cardiovascular death was developed, which was based on 11 risk factors (age, smoking cigarettes, systolic blood pressure, pulse pressure, ratio of total cholesterol/HDL-cholesterol, triglyceride, symptoms of coronary heart disease or heart failure, death of mother before 65 or death of father before 55 years due to myocardial infarction or stroke, energy in daily food intake and percentage of energy derived from saturated fatty acids). This model was applied to assess the probability of deaths between years 1984 and 2001, utilising data from screenings. RESULTS: The probability of death (in %) decreased from 1984 to 2001 by 11% in men. However, it remained stable for women. On the other hand the probability of cardiovascular death decreased by 25% and 33%, respectively. The main role in global risk decrease was played by beneficial trends in mean systolic blood pressure (in both genders) and percentage of smokers in men. CONCLUSIONS: Modification of life style influencing risk factors profile decreased the probability of death in the Warsaw population, correlating with changes in mortality rates.     

Obesity and the risk of cardiovascular disease and diabetes mellitus

The increasing prevalence of obesity worldwide has many experts concerned about the worsening health of a large proportion of the population. It is well recognized that obesity is associated with a higher mortality, an increased risk of hypertension and hyperlipidemia, cardiovascular disease, diabetes mellitus, osteoarthritis, gall bladder disease and possibly some cancers. Currently it is estimated that over two thirds of adults in the United States are overweight and nearly one third are clinically obese. Of special concern is the rapid increase     

Is the risk for cardiovascular disease increased in all phenotypes of the polycystic ovary syndrome?

Polycystic ovary syndrome (PCOS) is a common disorder in women of reproductive age, affecting around 10% of them. Polycystic ovary syndrome is considered to be related to increased risk for type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). There are 2 definitions for PCOS: one adopted in 1990 (classical PCOS with phenotypes A and B) and the other in 2003 (Rotterdam criteria with 4 phenotypes A to D). The latter is a wider definition including the 1990 phenotypes. There is mounting data suggesting that phenotypes C and D are not actually related to increased CVD risk, and thus screening for CVD risk factors of intervening for primary CVD prevention in young women is not cost-effective. There is an increasing number of suggestions to return to the 1990 criteria plus some metabolic parameters to identify real CVD risk in this population. However, such a strategy needs verification by large, prospective studies.     

Relationship of visceral adipose tissue to metabolic risk factors for coronary heart disease: is there a contribution of subcutaneous fat cell hypertrophy?

Visceral adipose tissue (VAT) accumulation is an important correlate of the metabolic complications found in obese patients. The aim of this study was to evaluate the respective contribution of VAT deposition versus subcutaneous abdominal or femoral fat cell hypertrophy as correlates of the metabolic risk profile in 69 men and 65 premenopausal women (aged 35+/-5 years) with a wide range of fatness (body mass index, 18 to 57 kg/m2). In both genders, VAT accumulation was positively correlated with fasting plasma insulin, triglyceride (TG), and low-density lipoprotein (LDL)-apolipoprotein B (apo B) levels and the cholesterol (CHOL)/high-density lipoprotein (HDL)-CHOL ratio (.24 < or = r < or = .71, P < .05). A similar pattern of positive relationships was found between subcutaneous abdominal fat cell weight and metabolic risk variables in men and women (.33 < or = r < or = .60, P < .01). Positive associations were also observed in women between femoral fat cell weight and fasting plasma insulin, TG, and CHOL levels and the CHOL/HDL-CHOL ratio (.29 < or = r < or = .42, P < .05). However, only plasma TG concentrations and the CHOL/HDL-CHOL ratio were positively correlated with femoral fat cell weight in men (r = .30, P < .05). To better investigate the relationships between the metabolic risk profile and hypertrophic subcutaneous obesity, individuals with small versus large subcutaneous abdominal adipocytes were matched according to VAT accumulation. Men with large abdominal fat cells displayed higher plasma TG and LDL-apo B levels compared with men characterized by small abdominal adipocytes (P < .05). Stepwise multiple regression analyses showed that subcutaneous abdominal fat cell weight was the best independent variable predicting plasma TG and LDL-apo B levels in men. No significant difference was found in the metabolic profile of subjects displaying small versus large femoral adipocytes. Taken together, these results suggest that for a given VAT deposition, the presence of hypertrophied subcutaneous abdominal adipocytes in men appears to be associated with further deterioration in the metabolic risk profile. On the other hand, the hypertrophy of femoral adipocytes does not further alter the metabolic complications generally related to obesity in both men and women.     

Metabolic syndrome and risk factors for cardiovascular disease: are nonagenarians protected?

This study assessed cardiovascular disease risk factors in three groups of human subjects aged 20–34 [young, 20 male (M)/33 female (F)], 60–74 (aged, 29M/29F), and > 90 years (nonagenarian, 47M/50F). Components of the metabolic syndrome, cardiovascular disease, and markers of inflammation and oxidative stress were assessed. Nonagenarians weighed less than the two other groups (P < 0.001); however, there was no difference in percent fat among the three groups. Aged individuals had the highest prevalence of the metabolic syndrome (P < 0.001) according to the Adult Treatment Panel III classification. Both fibrinogen and homocysteine concentrations were significantly higher in the nonagenarians compared to younger groups. However, there were no significant differences between groups in fasting insulin, high sensitive C-reactive protein, and plasminogen activator inhibitor 1 concentrations. There were also no relationships between inflammation/ oxidative stress and the metabolic syndrome or cardiovascular disease although nonagenarians appear to be protected from oxidative damage to DNA. Louisiana Healthy Aging Study  Meghan Allen, Arturo M. Arce, Mark A. Batzer, Lauri O. Byerley, Pauline Callinan, Cathy M. Champagne, Katie E. Cherry, Yu-wen Chiu, James P. DeLany, Melissa J. deVeer, Devon A. Dobrosielski, Andrea Ermolao, Elizabeth T. Fontham, Paula J. Geiselman, Valentina Greco, Sibte Hadi, Tiffany Hall, Karri Hawley, Scott W. Herke, Hui-Chen Hsu, Sangkyu Kim, Beth Kimball, Christina King-Rowley, Kim Landry, Li Li, Hui-Yi Lin, Kay Lopez, John D. Mountz, Emily Olinde, Kim Pedersen, Henry Rothschild, Ryan A. Russell, Donald Scott, Jennie Silva, Nicole Standberry, Jessica Thomson, Crystal Traylor, Cruz Velasco-Gonzalez, Jerilyn A. Walker, Xui Yun Wang, Michael A. Welsch, Robert H. Wood, Pili Zhang. Support  This research was supported by the Louisiana Board of Regents through the Millennium Trust Health Excellence Fund [HEF(2001–06)-02], by the National Institute on Aging (P01AG022064), and by the National Institute of General Medical Sciences (GM42056 and GM15431).     

Are thyroid peroxidase antibodies associated with cardiovascular disease risk in patients with subclinical hypothyroidism?

OBJECTIVE: Conflicting evidence has been reported about whether subclinical hypothyroidism (SCH) is associated with hyperlipidemia or cardiovascular disease. Thyroid peroxidase antibodies (TPOAb) are more common in persons with SCH. The purpose of this study was to evaluate whether the presence of (TPOAb) in people with SCH is associated with markers of cardiovascular disease. DESIGN: Cross-sectional study using multivariate regression. PATIENTS: Adults over age 40 who, in the National Health and Nutrition Examination Survey (NHANES) III, met the criteria for SCH (n = 188). MEASUREMENTS: Participants were stratified into TPOAb-negative (n = 82) and TPOAb-positive (n = 106) groups. Markers of cardiovascular disease risk were compared between the TPOAb-negative and TPOAb-positive groups. Multivariate regression models were performed to adjust for potential confounders. RESULTS: In bivariate analyses, individuals with and without TPOAb had similar levels of triglycerides, high-density lipoprotein, low-density lipoprotein, total cholesterol and C-reactive protein. Homocysteine levels were higher in the patients without antibodies (P = 0.01). After adjusting for, age, gender, smoking, hypertension, diabetes and use of a lipid-lowering medication, however, no statistically significant relationships were found between the presence of TPOAb and any of the cardiovascular risk markers. CONCLUSIONS: The presence of thyroid peroxidase antibodies does not appear to correlate with cardiovascular disease risk in patients with subclinical hypothyroidism. This study does not support the measurement of TPOAb antibodies in SCH as a strategy for guiding treatment or assessment of cardiovascular disease risk.     

Obesity--the risk factor of cardiovascular disease in patients with chronic kidney disease?

In general population obesity is regarded as a predisposing factor for chronic disease such as type 2 diabetes and cardiovascular disease. Obesity increases the risk of kidney disease and adversely affects the progress of kidney disease among patients with diagnosed kidney disease. The main reason of mortality in chronic kidney disease patients is cardiovascular disease, however, the real meaning of obesity as a risk factor of cardiovascular diseases is still uncertain. While in a general population obesity causes higher cardiovascular mortality, many studies reflect inverse association in chronic kidney disease patients. Obesity is associated with better survival, contrary to general population obesity appears to be a protective factor of cardiovascular disease. The name of this phenomenon is "reverse epidemiology" or "obesity paradox", in dialysis patients known as a "risk-factor-paradox". Some studies do not confirm this paradox association in patients with chronic kidney disease.